Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYNAMRO vs BUMETANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Adjunct to lipid-lowering medications and diet to reduce LDL-C, apo B, total cholesterol, and non-HDL-C in patients with homozygous familial hypercholesterolemia (Ho FH)
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Primarily metabolized by endonucleases and exonucleases. Not a substrate for CYP450 enzymes.
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Greater than 90% bound to plasma proteins, predominantly albumin.
Approximately 95% bound, primarily to albumin.
Approximately 9.6 L/kg, indicating extensive tissue distribution (e.g., liver, kidney).
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
Subcutaneous administration: approximately 90% bioavailability; not administered intravenously clinically.
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
No dose adjustment is required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis; use with caution.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Safety and efficacy in pediatric patients have not been established; not recommended for use in patients under 18 years of age.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
No specific dose adjustments for elderly patients; clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
Risk of hepatotoxicity: Kynamro can cause elevations in serum transaminases and hepatic steatosis. Monitor liver function before and during treatment. Do not use in patients with moderate or severe hepatic impairment.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
Hepatotoxicity: monitor ALT, AST, alkaline phosphatase, and total bilirubin before each dose; discontinue if clinically significant toxicity occurs.,Hepatic steatosis: may cause fatty liver; advise patients to report symptoms of liver injury.,Injection site reactions: common and may be severe.,Flu-like symptoms: common; may require symptomatic treatment.,Allergic reactions: including angioedema and urticaria.,Immune system effects: possible development of anti-drug antibodies and platelet count reductions.
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Moderate or severe hepatic impairment (Child-Pugh class B or C),Hypersensitivity to mipomersen or any component of the formulation,Active liver disease or unexplained persistent elevations of serum transaminases
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Avoid high-fat meals before and after injection. Take KYNAMRO at least 2 hours after any food and at least 1 hour before the next meal to minimize gastrointestinal side effects. No specific food-drug interactions known; however, the drug can increase hepatic fat, so a low-fat diet is generally recommended.
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended during pregnancy unless clearly necessary.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
It is unknown if KYNAMRO is excreted in human milk. No M/P ratio available. A risk to the breastfed infant cannot be excluded; decision to discontinue breastfeeding or drug should consider importance of drug to mother.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
No pharmacokinetic studies in pregnancy. No specific dose adjustment recommended; use only if potential benefit justifies potential risk. Standard dose: 200 mg subcutaneously once weekly.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
KYNAMRO (mipomersen) is an antisense oligonucleotide for homozygous familial hypercholesterolemia (Ho FH). It reduces LDL-C by inhibiting apo B-100 synthesis. Monitor for hepatotoxicity; require ALT, AST, alkaline phosphatase, and bilirubin before each dose. Injection site reactions are common; rotate sites. Consider a statin first-line in Ho FH if tolerated; mipomersen is adjunctive. Avoid in patients with significant liver disease or unexplained persistent transaminase elevations. Do not use in pregnancy due to risk of embryofetal toxicity.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
KYNAMRO is a weekly injection under the skin for homozygous familial hypercholesterolemia.,You must have blood tests to check your liver before each dose.,Common side effects include injection site redness, swelling, pain, or itching; flu-like symptoms; and nausea.,Do not take KYNAMRO if you are pregnant or planning to become pregnant; use effective contraception.,Take KYNAMRO on the same day each week, at least 2 hours after a meal and at least 1 hour before any food or other oral medications.,Store KYNAMRO in the refrigerator; do not freeze. Allow to warm to room temperature for 30 minutes before injecting.,Contact your doctor immediately if you experience yellowing of skin or eyes, dark urine, or severe abdominal pain.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYNAMRO vs BUMETANIDE, answered by our medical review team.
KYNAMRO is a Antilipemic that works by Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the m RNA of apolipoprotein B-100 (apo B-100), inhibiting its translation and reducing the production of apo B-100-containing lipoproteins, including LDL, VLDL, and Lp(a).. BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYNAMRO and BUMETANIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYNAMRO is: Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.. The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYNAMRO and BUMETANIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYNAMRO is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no fetal harm was observed; however, caution is advised. KYNAMRO is not recommended durin. BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.